HIV Rev-­dependent Reporter Cells

Product Description Before proceeding to add the product to cart, please either fill out and submit the form, or download the PDF version. You can email a signed MTA to [email protected]. Please note that, one of our officers will review the order and you will receive an email regarding the order status. Once approved, you will receive an email with the payment link. Download the PDF version here × Biological Material Transfer Agreement Between Virongy Biosciences Inc at 11225 Asseett Loop, Lab 111, Manassas, VA, 20109 (Provider) Recipient (Recipient) Upon execution of an Implementing Letter in the form attached which specifies the materials to be transferred, organizations agree to be bound by the terms of this Biological Material Transfer Agreement ("BMTA") published in the Federal Register on March 8, 1995. I. Definitions: PROVIDER: Organization providing the ORIGINAL MATERIAL. The name and address of this party will be specified in an implementing letter. PROVIDER SCIENTIST: The name and address of this party will be specified in an implementing letter. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The name and address of this party will be specified in an implementing letter. RECIPIENT SCIENTIST: The name and address of this party will be specified in an implementing letter. ORIGINAL MATERIAL: The description of the material being transferred will be specified in an implementing letter. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met. NONPROFIT ORGANIZATION(S): A university or other institution of higher education or an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 U.S.C. 501(a)) or any nonprofit scientific or educational organization qualified under a state nonprofit organization statute. As used herein, the term also includes government agencies. II. Terms and Conditions of this Agreement: The PROVIDER retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICATIONS. The RECIPIENT and the RECIPIENT SCIENTIST agree that the MATERIAL: will NOT be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of the PROVIDER; is to be used only at the RECIPIENT organization and only in the RECIPIENT SCIENTIST's laboratory under the direction of the RECIPIENT SCIENTIST or others working under his/her direct supervision; and will not be transferred to anyone else without the prior written consent of the PROVIDER. will NOT be used for any commercial purpose without the prior written consent of the PROVIDER. will NOT be reproduced, modified, or reverse engineered without the written consent of the PROVIDER. will NOT disclose any confidential information provided to the RECIPIENT by the PROVIDER. The RECIPIENT acknowledges that the MATERIAL is the subject of patent applications. No express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made by the PROVIDER or the RECEIPENT. In particular, no express or implied licenses or other rights are provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. The PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS, NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER. This agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the MATERIAL or the MODIFICATIONS. The RECIPIENT agrees to inform the PROVIDER three months before the intended publication of results, and appropriate acknowledgement of the source of the MATERIAL in all publications. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable local statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA. This Agreement will terminate on the earliest of the following dates: (a) on completion of the RECIPIENT's current research with the MATERIAL, or (b) on thirty (30) days written notice by either party. if termination should occur under 8(a), the RECIPIENT shall be bound to the PROVIDER by the restrictive terms applicable to the MATERIAL. if termination should occur under 8(b), the RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS; Client Signature Brian Hetrick, Ph.D Client Name Chief Executive Officer Client Title Virongy Biosciences Inc. Client Organization Date Date Submit Product Description Product Specifications Documentation References Product Description HIV Rev-dependent reporter cellsApplications:TCID50 assays: Routine HIV infectivity & quantificationAnti-HIV drug screenings via one-step infectionRoutine EC50/LD50 quantifications of anti-HIV compoundsScreenings for broadly neutralizing antibodies (bnAB) (from laboratory and clinical research samples)Neutralizing antibody quantificationsHIV cell-cell transmission and HIV drug-resistance studiesHIV host restriction factor (HRF) studiesHIV host dependency factor (HDF) studiesLow-level HIV gene expression assessmentsHIV pre-integration transcription studiesHIV latency and reactivation studiesHIV outgrowth detection following reactivationHIV tropism determinationsThe HIV Rev-dependent reporter cells represent a major advancement in the development of HIV indicator cells (Wu et al., 2007). This new reporter system differs dramatically from the common LTR-based reporter cells, which rely solely on the HIV promoter, the long terminal repeat (LTR), to drive reporter expression. While responsive to an early HIV protein, Tat, the LTR is also responsive to cell culture conditions and stimulation by a variety of known and unknown factors, including cytokines, mitogens, HDAC inhibitors, lipopolysaccharide, certain anti-tumor drugs, and free viral proteins (Siekevitz et al., 1987; Sweet et al., 1995). Such non-HIV-dependent reporter expression frequently diminishes reporter specificity and sensitivity. In contrast to the LTR-based reporter cells, our Rev-dependent reporter cells use both LTR and the Rev/RRE interaction to regulate reporter gene expression. This strict requirement for Rev, a viral protein present only in infected cells, drastically improves the reporter specificity and sensitivity. As a result, our Rev-dependent reporter cells are suitable for a broad range of applications, including screening broadly neutralizing antibodies and anti-HIV drugs, and studying HIV cell-cell transmission and host restriction and dependency factors. Derived from CD4 T cells, our reporter cells express native levels of HIV receptors and are natural HIV targets with broad susceptibility to X4, R5, primary HIV isolates, and certain SIV strains. With GFP, Luc, or GFP/Luc detection options, our Rev-dependent cells provide a versatile and flexible platform for HIV research.Highlights:Unparalleled sensitivity & specificity: Rev-regulated reporter expressionVersatile: GFP & Luciferase dual reporter systemNatural HIV target: Derived from human CD4 T cellsPhysiologically relevant: Natural levels of HIV receptors/co-receptorsBroad susceptibility: Susceptible to X4, R5, primary HIV isolates, some SIVGreen or Firefly Reporters AvailableHave you ever mis-timed your assays only to have all your cells turn blue? Does the X-Gal staining picture look all too familiar? Our Rev-dependent reporter cells eliminate the potential for false positive signals arising because your current indicator cells turned blue without HIV infection or because you did not perfectly time your X-Gal staining. With unparalleled specificity and sensitivity, our Rev-dependent reporter cells come with a GFP, Luciferase, or combination GFP/Luciferase reporter that provides ease of use and flexibility.Greater HIV Sensitivity and Specificity – Minimal Background SignalNearly all HIV indicator cells use the LTR promoter to drive reporter expression. While the LTR promoter is responsive to HIV Tat, it generates false positive reporter expression due to HIV-independent factors, resulting in lower HIV specificity and a lower HIV detection range. Changes in cell culture conditions and the presence of mitogens, cytokines, cellular activators, and chromatin modulators can all produce background signal in LTR reporters. Our Rev-dependent reporter cells overcome the drawbacks of LTR reporter lines by being engineered to use the interaction between HIV Rev and RRE (Rev-Response Element) to regulate reporter expression. Rev is present only in HIV cells. The high stringency that Rev imposes on the reporter dramatically decreases background signal and significantly increases sensitivity. Thus, our Rev-dependent reporter cells specifically detect low levels of HIV replication even in the presence of environmental factors that generate false signal with the LTR promoter.Our Rev-dependent reporter cells carry stably integrated reporter constructs that are derived from the HIV genome. The incorporation of RRE and multiple, authentic HIV splicing sites permits reporter expression only from the non-spliced and singly-spliced transcripts in the presence of Rev.Our Rev-dependent reporter cells are highly HIV-specific when compared with the LTR-GFP indicator cells. Without HIV, our reporter cells have undetectable GFP, whereas the LTR-GFP cells have high background GFP. Our Rev-dependent reporter cells do not respond to PMA stimulation (100 ng ml-1), while the LTR-GFP cells respond to PMA stimulation by producing high levels of GFP signal in the absence of HIV.Thoroughly CharacterizedEach of our cell lines has been thoroughly characterized and validated with regards to HIV responsiveness and sensitivity to anti-HIV inhibitors, HIV activators, and HIV neutralizing antibodies. Our reporter cells are derived from human T cells and carry physiological or near-physiological levels of HIV receptors and relevant T-cell receptors. As such, our reporter cells are especially suited for quantifying HIV isolates and bnABs using laboratory and clinical research samples. Greater Physiological RelevanceOur Rev-dependent reporter cells are derived from CD4 T cells such as CEM-SS (Wu et al., 2007) and A3R5 (McLinden et al., 2013), and are further engineered with a dual LTR and Rev-dependent reporter system. Because they are derived from CD4 T cells and do not contain a superabundance of HIV receptors, our reporter cells provide a physiologically relevant and nAB-sensitive reporter system.Receptor cell density of A3R5 cells. Source: PLOS ONE, McLinden et al. 2013, 8: 11, e77756. Our Rev-dependent Cell Lines (derived from CEM-SS & A3.01 cells) do not have a superabundance of receptors and more closely mimic natural T-cell HIV receptor densities.Examples of ApplicationQuantification of HIV neutralizing antibodiesPrior to infection, HIV(AD8), an R5 virus, was incubated with or without the HIV neutralizing antibody B12 (10 μg ml-1 final). After 1 h, Rev-A3R5-GFP cells were infected with Ab-neutralized and non-neutralized virus. Cells were washed and cultured for 48 hours. GFP expression was quantified by flow cytometry. PI = propidium iodide.One Step Anti-HIV Drug Screening with the Rev-dependent GFP/Luc Reporter CellEasy to Use: One Infection, Three Readouts. Increase the efficiency of your screening process by simplifying your protocol. With our Rev-dependent reporter cell system, three readouts may be generated with one infection. Easily screen for positive candidates based on the luciferase signal and then obtain population dynamics through flow cytometry based on the fluorescent signal of GFP and/or a vital dye.The Making of the Rev-dependent Reporter CellsThe HIV Rev-dependent Reporter cell lines were originally developed by Wu & Marsh at the National Institutes of Health. The first generation of the Rev-dependent cell, Rev-CEM, has been used extensively in multiple laboratories for studying HIV infection, anti-HIV drugs, and HIV cell-cell transmission. Multiple Rev-dependent Reporter cells have been developed recently to meet the needs of the HIV/AIDS research community. Example Protocol: HIV Infection of Rev-dependent reporter cells(When using HIV Rev-dependent Reporter cells, use of HIV InfectinTM is required)1. Count cells to be infected, and pellet cells by centrifugation at 300 x g for 5 minutes.Note: Cell viability should be ≥ 80%.2. Resuspend cells in complete media at a concentration of ~2 x 106 cells ml-1.3. Use 100 μl of cells (~2 x 105 cells) per infection.4. Pre-treat cells by adding 10 μl of HIV Infectin (10X) so that the HIV Infectin concentration is 1X. Mix and incubate for 2 hours.5. Add virus to the cells and mix. Note volume of virus used.6. Add HIV Infectin in an amount equal to 1/10 of the virus volume used. For example, if 100 μl of virus is used, add 10 μl of HIV Infectin. Incubate at 37°C for 2–4 hours.7. Wash cells by adding an additional 1 ml fresh complete media, pelleting cells as in 1) above, and removing supernatant. (Optional) Repeat once for a total of two washes.8. After washing, resuspend cells in 1 ml complete medium.9. Culture and utilize cells as usual. Product Specifications Documentation HIV Rev-Dependent Reporter Cell Line – MSDSHIV Rev-Dependent Reporter Cell Line – Handbook References Wu Y, Beddall MH, Marsh JW. Rev-dependent indicator T cell line. Current HIV Research. 2007; 5:395-403.Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC. Activation of the HIV-1 LTR by T cell mitogens and the transactivator protein of HTLV-I. Science. 1987; 238:1575–1578.Sweet MJ, Hume DA. RAW264 macrophages stably transfected with an HIV-1 LTR reporter gene provide a sensitive bioassay for analysis of signalling pathways in macrophages stimulated with lipopolysaccharide, TNF-alpha or taxol. J Inflamm. 1995; 45:126 –135.Yu D, Wang W, Yoder A, Spear M, Wu Y. The HIV envelope but not VSV glycoprotein is capable of mediating HIV latent infection of resting CD4 T cells. PLoS Pathog. 2009; 5(10):e1000633. PubMed PMID: 19851458.Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature. 2011; 477(7362):95-8. PubMed PMID: 21849975.Yoder A, Yu D, Dong L, Iyer SR, Xu X, Kelly J, et al. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell. 2008; 134(5):782-92. PubMed PMID: 18775311.Spear M, Guo J, Turner A, Yu D, Wang W, Meltzer B, et al. HIV-1 triggers WAVE2 phosphorylation in primary CD4 T cells and macrophages, mediating Arp2/3-dependent nuclear migration. J Biol Chem. 2014; 289(10):6949-59. PubMed PMID: 24415754; PubMed Central PMCID: PMC3945356.Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA. Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of major histocompatibility complex class I via Nef. J Virol. 2011; 85(6):2828-36. PubMed PMID: 21209113.Shuck-Lee D, Chang H, Sloan EA, Hammarskjold ML, Rekosh D. Single-nucleotide changes in the HIV Rev-response element mediate resistance to com-pounds that inhibit Rev function. J Virol. 2011; 85(8):3940-9. PubMed PMID: 21289114.Guo J, Wang W, Yu D, Wu Y. Spinoculation triggers dynamic actin and cofilin activity facilitating HIV-1 infection of transformed and resting CD4 T cells. J Virol. 2011; 85(19):9824-33. PubMed PMID: 21795326.HIV Rev-dependent Reporter Cells may be obtained with a Limited Use License. HIV Rev-dependent Reporter Cells are intended for research use only and are not for diagnostic or therapeutic purposes or uses in humans or animals.